All In MedTech

FDA Clearance Tracker · P000043

TMX-2000 BPH THERMOTHERAPY SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2001 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 29, 2001

Approval withdrawn

Time to decision

256 days

Received Oct 16, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P000043
Device name
TMX-2000 BPH THERMOTHERAPY SYSTEM
Applicant location
Marlboro, MA
Received
Oct 16, 2000
Decided
Jun 29, 2001
Decision
Approval withdrawn
Supplements
20 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE TMX-2000(TM) BPH THERMOTHERAPY SYSTEM. THE DEVICE IS INDICATED AS A NON-SURGICAL DEVICE FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WHO HAVE A MINIMUM PROSTATIC URETHRA LENGTH OF 30 MM AND A TOTAL PROSTATE VOLUME BETWEEN 30 AND 100 CC.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MEQ. The earliest in FDA's data is P950014, decided May 3, 1996.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.